You are here: Industry Insights > Sanofi

News List

Sanofi and Translate Bio Expand Vaccine Collaboration contractpharma
June 28, 2020
To develop mRNA vaccines across all infectious disease areas in a deal potentially worth up to $1.9 billion.
Sanofi and Translate Bio team up to develop mRNA vaccines pharmaceutical-technology
June 24, 2020
Sanofi vaccines business unit Sanofi Pasteur has expanded its existing 2018 partnership with messenger RNA (mRNA) therapeutics firm Translate Bio for the development of mRNA vaccines against various infectious diseases.
Sanofi eyes approval of COVID-19 vaccine by first half of 2021 expresspharma
June 24, 2020
Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021.
Sanofi-Regeneron Dupixent secures China approval for atopic dermatitis pharmaceutical-technology
June 23, 2020
Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) has received approval from China’s National Medical Products Administration (NMPA) to treat adults with moderate to severe atopic dermatitis.
Sanofi Invests $679M in Two French Vaccine Sites contractpharma
June 17, 2020
Will create a state-of-the-art vaccine production site and a new research center dedicated to vaccines.
NICE rejects Sanofi's Cablivi in draft guidelines pharmatimes
June 16, 2020
NICE has drawn up draft guidelines rejecting Sanofi's Cablivi (caplacizumab) for use alongside plasma exchange and immunosuppression for treating an acute episode of acquired thrombotic thrombocytopenic purpura (TTP).
NICE rejects Sanofi's Sarclisa in preliminary guidelines pharmatimes
June 09, 2020
NICE has published initial guidelines rejecting NHS use of a therapy combination containing Sanofi's Sarclisa (isatuximab) to treat multiple myeloma.
Sanofi hands back rights to Oxford Biomedica gene therapies pharmatimes
June 09, 2020
Sanofi is handing back rights to two gene therapy programmes it acquired from Oxford Biomedica more than 10 years ago.
Sanofi secures EC approval for Sarclisa for third-line multiple myeloma pharmaceutical-business-review
June 08, 2020
Sanofi has secured approval from the European Commission (EC) for Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of relapsed and refractory multiple myeloma (MM) in adult patients.
Sanofi gets EC approval for Sarclisa to treat multiple myeloma pharmaceutical-technology
June 04, 2020
Sanofi has received approval from the European Commission (EC) for the use of Sarclisa (isatuximab) with pomalidomide and dexamethasone (pom-dex) to treat adults with relapsed and refractory multiple myeloma (MM).